Tinostamustine for use in treating ovarian cancer

A method of treating ovarian cancer in a patient in need thereof, comprising administering to said patient an effective amount of tinostamustine or a pharmaceutically acceptable salt thereof, and carboplatin;

• wherein tinostamustine or pharmaceutically acceptable salt thereof is administered at a dosage level of from 60 to 150 mg/m2 body surface area of the patient;
• and,
• wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof on days 1, 8 and 15 of a 28-day treatment cycle.